Wen Hwa Lee is the CEO and Chief Scientist at Action Against AMD (Age-Related Macular Degeneration), a research charity focused on tackling the leading cause of legal blindness in the developed world at its earliest stages with maximum affordability and accessibility.
He is also a co-director of Oxford Martin School’s Affordable Medicines Programme. Trained in genetics and molecular/structural biology, he is an experienced leader in setting up partnerships and alliances with multiple stakeholders to accelerate discoveries for drug discovery.
Wen Hwa Lee designed and implemented several open science strategies in two of the largest and most successful international public-private partnerships for drug
discovery – the Structural Genomics Consortium (SGC) and the European Lead Factory.
Wen Hwa Lee works alongside the ODI in his role on HDRUK INSIGHT Hub’s Leadership Team. He leads the creation of its Data Trust Advisory Board (DataTAB) to bring in public and patients at Governance level for a transparent, fair and accountable use of health data.